Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Down0.10% Nasdaq Up0.23%

Forest Laboratories Inc. (FRX)

-NYSE
89.58 Down 0.71(0.79%) Apr 17, 4:00PM EDT
|After Hours : 89.58 0.00 (0.00%) Apr 17, 4:29PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Forest Laboratories Inc.
909 Third Avenue
New York, NY 10022
United States - Map
Phone: 212-421-7850
Website: http://www.frx.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:5,800

Business Summary 

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company’s products include Linzess for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation; Tudorza Pressair, an antimuscarinic agent to treat bronchospasm associated with chronic obstructive pulmonary disease; Viibryd for the treatment of adults with major depressive disorder (MDD); and Daliresp, a phosphodiesterase-4 enzyme inhibitor to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in patients with severe COPD. Its products also comprise Teflaro for the treatment of adults with skin and skin structure infections; Bystolic to treat hypertension; Namenda and Namenda XR for the treatment of moderate and severe Alzheimer's disease; Savella to treat fibromyalgia; and Colobreathe, a dry powder inhaler for the treatment of chronic lung infections. In addition, the company develops Levomilnacipran, which is under Phase III clinical trials for the treatment of MDD; Cariprazine that is in Phase III clinical trials to treat acute exacerbation of schizophrenia and acute mania associated with bipolar disorder; ceftazidime/avibactam, which is under Phase III clinical trials for intra-abdominal infections and for complicated urinary tract infections; and Cebranopadol (GRT 6005) that has completed Phase II clinical trials for moderate to severe chronic pain conditions. Forest Laboratories, Inc. sells its products directly to physicians, pharmacies, hospitals, managed care, and other healthcare organizations, as well as through independent distributors. It has collaborative licensing option agreement with Trevena for the development of TRV027 for the treatment of acute decompensated heart failure; and collaboration agreement with Ironwood develop and commercialize Linzess. The company was founded in 1956 and is headquartered in New York, New York.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Forest Laboratories Inc.

Corporate Governance 
Forest Laboratories Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 2. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 3.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. Howard Solomon , 86
Non-Exec. Chairman and Sr. Advisor
1.90M0.00
Mr. Brenton L. Saunders J.D., 44
Chief Exec. Officer, Pres, Director, Chairman of Compensation Committee and Member of Compliance Committee
139.00KN/A
Mr. Francis I. Perier Jr., 54
Chief Financial Officer, Exec. VP and Member of Disclosure, Legal Compliance & Risk Management Committee
948.00K0.00
Mr. David F. Solomon , 48
Sr. VP of Corp. Devel. & Strategic Plan and Sr. Advisor to the Chief Exec. Officer
695.00K0.00
Ms. Elaine Hochberg , 57
Exec. VP of International, Strategic Planning & Gov. Affairs and Member of Disclosure, Legal Compliance & Risk Management Committee
1.02M0.00
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders